MGF
Also known as: Mechano Growth Factor, IGF-1 Ec, Exercise-Induced IGF-1
MGF research concerns IGF-1 splice biology and synthetic E-domain peptides. Positive and negative cell studies do not establish targeted human muscle growth or a validated injection schedule.
Quick Facts
Overview
Mechano growth factor (MGF) is used in research discussions of IGF-1 splice variants and their distinct E domains. A synthetic E-domain fragment is not the same intervention as exercise-induced gene expression, the full IGF-1 precursor or mature IGF-1.
The human-derived muscle study treated isolated cells in culture; it did not inject people to test muscle gain.
Mechanism of Action
An original cell experiment reported greater myoblast proliferation and delayed terminal differentiation with an MGF E-domain peptide, with results suggesting a mechanism distinct from mature IGF-1 receptor signaling.
However, a later replication study found no apparent effect on proliferation, differentiation or selected signaling responses, despite responses to mature IGF-1 or the full precursor. Mechanism and preparation remain contested; local injection does not itself prove targeted growth.
Potential Benefits
The 2011 culture study reported favorable effects on human muscle progenitor cells, with responses differing by donor age. This is a useful repair-research signal, not a clinical sarcopenia or athletic-recovery outcome.
The negative replication limits confidence in generalizing the cell mechanism. Neither study demonstrates selective hypertrophy of an injected muscle or a predictable gain in pounds.
Dosing and Administration
The reviewed cell-culture experiment and replication work do not establish a human dose, route or injection timing. Laboratory concentrations cannot be converted directly into a post-workout microgram protocol.
A universal 30-minute window, required direct-muscle injection, 2–3-hour human half-life and combination schedule with IGF-1 LR3 were not validated by these sources.
Research and Evidence
| Source | Design | Finding and limit |
|---|---|---|
| Early E-domain study | In-vitro myoblast model | Positive proliferation/differentiation observations; not human treatment. |
| Human progenitor cultures | Isolated cells from donors of different ages | Encouraging age-dependent responses; people were not treated. |
| Replication study | Human/mouse cells; native/stabilized peptides | No apparent effect in the tested assays; mature IGF-1 controls responded. |
Both favorable and unfavorable original findings matter. Human-derived cells should not be classified as an administered-human efficacy trial, and results for a particular fragment should not be transferred to a PEGylated product or full precursor.
Side Effects and Considerations
The original positive paper proposed a therapeutic rationale; it did not demonstrate absence of cancer risk or systemic adverse effects from treatment in people. The replication paper does not provide a clinical safety program either.
Clinical adverse-event rates, interactions and long-term safety remain unestablished in this reviewed evidence. An intended local mechanism does not guarantee that injected material stays local or is well tolerated.
Conclusion
MGF is an interesting but disputed research area. The positive human-cell findings and negative replication justify careful study of preparation and mechanism, rather than a proven muscle-targeting injection protocol.
Source Review and Evidence Limits
Original early cell, human-derived culture and replication indexed abstracts were read. Their journal full texts were not obtained. This bounded assessment separates expression biology, full precursor, isolated fragment and clinical use; it is not an exhaustive human-trial or US product-application search, clinician sign-off or family certification.
Frequently Asked Questions About MGF
The reviewed evidence does not establish an optimal human injection time. Cell experiments cannot validate an immediately-post-workout or 30-minute dosing window.
The cited studies do not establish an administered-human growth benefit with or without training. Exercise-responsive gene expression and an injected synthetic fragment are different questions.
A predictable gain of 3–8 pounds, or selective growth in injected muscles, was not demonstrated by the reviewed original studies.
A required human intramuscular route, or superiority over subcutaneous delivery, was not established. Directly treating isolated cells is not a clinical route comparison.
The reviewed sources do not establish benefit or safety of an MGF/IGF-1 LR3 combination. A proposed complementary mechanism is not a tested stack.
The reviewed evidence does not establish a universal 2–3-hour human half-life or days-long growth response after injection. Duration depends on the actual preparation and must be measured rather than inferred from splice biology.
Related Peptides
Continue exploring MGF
Search all related references →Our library review is ongoing. Read how we evaluate evidence or report a correction.
Disclaimer: This article is for informational and educational purposes only. It is not intended as medical advice. The information presented is based on published research and should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting any peptide protocol. Some peptides discussed may not be approved for human use by the FDA or equivalent regulatory bodies.